Putting together the psoriasis puzzle: An update on developing targeted therapies

Leanne M. Johnson-Huang, Michelle A. Lowes, James G. Krueger

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Psoriasis vulgaris is a chronic, debilitating skin disease that affects millions of people worldwide. There is no mouse model that accurately reproduces all facets of the disease, but the accessibility of skin tissue from patients has facilitated the elucidation of many pathways involved in the pathogenesis of psoriasis and highlighted the importance of the immune system in the disease. The pathophysiological relevance of these findings has been supported by genetic studies that identified polymorphisms in genes associated with NFκB activation, IL-23 signaling and T helper 17 (Th17)-cell adaptive immune responses, and in genes associated with the epidermal barrier. Recently developed biologic agents that selectively target specific components of the immune system are highly effective for treating psoriasis. In particular, emerging therapeutics are focused on targeting the IL-23-Th17-cell axis, and several agents that block IL-17 signaling have shown promising results in early-phase clinical trials. This review discusses lessons learned about the pathogenesis of psoriasis from mouse-and patient-based studies, emphasizing how the outcomes of clinical trials with T-cell-targeted and cytokine-blocking therapies have clarified our understanding of the disease.

Original languageEnglish (US)
Pages (from-to)423-433
Number of pages11
JournalDMM Disease Models and Mechanisms
Volume5
Issue number4
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Psoriasis
Interleukin-23
Th17 Cells
Immune system
Skin Diseases
Skin
Genes
Clinical Trials
T-cells
Interleukin-17
Immune System Diseases
Biological Factors
Adaptive Immunity
Therapeutics
Polymorphism
Immune System
Chemical activation
Outcome Assessment (Health Care)
Tissue
Cytokines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Putting together the psoriasis puzzle : An update on developing targeted therapies. / Johnson-Huang, Leanne M.; Lowes, Michelle A.; Krueger, James G.

In: DMM Disease Models and Mechanisms, Vol. 5, No. 4, 07.2012, p. 423-433.

Research output: Contribution to journalArticle

Johnson-Huang, Leanne M. ; Lowes, Michelle A. ; Krueger, James G. / Putting together the psoriasis puzzle : An update on developing targeted therapies. In: DMM Disease Models and Mechanisms. 2012 ; Vol. 5, No. 4. pp. 423-433.
@article{4c356ebb92f94d90a505d30e729e4d62,
title = "Putting together the psoriasis puzzle: An update on developing targeted therapies",
abstract = "Psoriasis vulgaris is a chronic, debilitating skin disease that affects millions of people worldwide. There is no mouse model that accurately reproduces all facets of the disease, but the accessibility of skin tissue from patients has facilitated the elucidation of many pathways involved in the pathogenesis of psoriasis and highlighted the importance of the immune system in the disease. The pathophysiological relevance of these findings has been supported by genetic studies that identified polymorphisms in genes associated with NFκB activation, IL-23 signaling and T helper 17 (Th17)-cell adaptive immune responses, and in genes associated with the epidermal barrier. Recently developed biologic agents that selectively target specific components of the immune system are highly effective for treating psoriasis. In particular, emerging therapeutics are focused on targeting the IL-23-Th17-cell axis, and several agents that block IL-17 signaling have shown promising results in early-phase clinical trials. This review discusses lessons learned about the pathogenesis of psoriasis from mouse-and patient-based studies, emphasizing how the outcomes of clinical trials with T-cell-targeted and cytokine-blocking therapies have clarified our understanding of the disease.",
author = "Johnson-Huang, {Leanne M.} and Lowes, {Michelle A.} and Krueger, {James G.}",
year = "2012",
month = "7",
doi = "10.1242/dmm.009092",
language = "English (US)",
volume = "5",
pages = "423--433",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "4",

}

TY - JOUR

T1 - Putting together the psoriasis puzzle

T2 - An update on developing targeted therapies

AU - Johnson-Huang, Leanne M.

AU - Lowes, Michelle A.

AU - Krueger, James G.

PY - 2012/7

Y1 - 2012/7

N2 - Psoriasis vulgaris is a chronic, debilitating skin disease that affects millions of people worldwide. There is no mouse model that accurately reproduces all facets of the disease, but the accessibility of skin tissue from patients has facilitated the elucidation of many pathways involved in the pathogenesis of psoriasis and highlighted the importance of the immune system in the disease. The pathophysiological relevance of these findings has been supported by genetic studies that identified polymorphisms in genes associated with NFκB activation, IL-23 signaling and T helper 17 (Th17)-cell adaptive immune responses, and in genes associated with the epidermal barrier. Recently developed biologic agents that selectively target specific components of the immune system are highly effective for treating psoriasis. In particular, emerging therapeutics are focused on targeting the IL-23-Th17-cell axis, and several agents that block IL-17 signaling have shown promising results in early-phase clinical trials. This review discusses lessons learned about the pathogenesis of psoriasis from mouse-and patient-based studies, emphasizing how the outcomes of clinical trials with T-cell-targeted and cytokine-blocking therapies have clarified our understanding of the disease.

AB - Psoriasis vulgaris is a chronic, debilitating skin disease that affects millions of people worldwide. There is no mouse model that accurately reproduces all facets of the disease, but the accessibility of skin tissue from patients has facilitated the elucidation of many pathways involved in the pathogenesis of psoriasis and highlighted the importance of the immune system in the disease. The pathophysiological relevance of these findings has been supported by genetic studies that identified polymorphisms in genes associated with NFκB activation, IL-23 signaling and T helper 17 (Th17)-cell adaptive immune responses, and in genes associated with the epidermal barrier. Recently developed biologic agents that selectively target specific components of the immune system are highly effective for treating psoriasis. In particular, emerging therapeutics are focused on targeting the IL-23-Th17-cell axis, and several agents that block IL-17 signaling have shown promising results in early-phase clinical trials. This review discusses lessons learned about the pathogenesis of psoriasis from mouse-and patient-based studies, emphasizing how the outcomes of clinical trials with T-cell-targeted and cytokine-blocking therapies have clarified our understanding of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84863472728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863472728&partnerID=8YFLogxK

U2 - 10.1242/dmm.009092

DO - 10.1242/dmm.009092

M3 - Article

C2 - 22730473

AN - SCOPUS:84863472728

VL - 5

SP - 423

EP - 433

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 4

ER -